EFAVIRENZ + LAMIVUDINE + TENOFOVIR

The combination of efavirenz, lamivudine, and tenofovir is used in the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children (from 12 years of age and weighing less than 40kg) with virologic suppression to HIV-1 RNA levels of less than 50 copies/ml on their current combination antiretroviral therapy for more than three months. Efavirenz belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Lamivudine and tenofovir belong to the class of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs).